

1     **Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in**  
2                   **schools in Switzerland: design for a longitudinal, school-based**  
3                   **prospective cohort study**

4  
5     <sup>1</sup>Agne Ulyte\*, <sup>1</sup>Thomas Radtke\*, <sup>2</sup>Irène Abela, <sup>1</sup>Sarah R Haile, <sup>1</sup>Julia Braun, <sup>1</sup>Ruedi Jung,

6     <sup>3</sup>Christoph Berger, <sup>2</sup>Alexandra Trkola, <sup>1</sup>Jan Fehr, <sup>1</sup>Milo A. Puhan, <sup>1</sup>Susi Kriemler

7     \* shared first authorship

8  
9     **Affiliations:**

10    <sup>1</sup> Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich,  
11    Switzerland;

12    <sup>2</sup> Institute of Medical Virology, University of Zurich, Zürich, Switzerland;

13    <sup>3</sup> University Children's Hospital Zurich, Division of Infectious Diseases, Zürich, Switzerland

14  
15    **Trial registration:** ClinicalTrials.gov Identifier: NCT04448717, registered June 26, 2020.

16    <https://clinicaltrials.gov/ct2/show/NCT04448717>

17  
18    **Address correspondence to:** Susi Kriemler, University of Zurich, Epidemiology,

19    Biostatistics and Prevention Institute (EBPI), Hirschengraben 84, 8001 Zürich, Switzerland.

20    Tel: +41 44 634 63 20, [susi.kriemlerwiget@uzh.ch](mailto:susi.kriemlerwiget@uzh.ch)

21

22 **Abstract**

23 **Introduction** Seroprevalence and transmission routes of severe acute respiratory syndrome  
24 coronavirus 2 (SARS-CoV-2) infection in children and adolescents, especially in school  
25 setting, are not clear. Resulting uncertainty is reflected in very different decisions on school  
26 closures and reopenings across countries. The aim of this longitudinal cohort study is to  
27 assess the extent and patterns of seroprevalence of SARS-CoV-2 antibodies in school-  
28 attending children repeatedly. It will examine risk factors for infection, relationship between  
29 seropositivity and symptoms, and temporal persistence of antibodies. Additionally, it will  
30 include testing of school personnel and parents.

31 **Methods and analysis** The study (*Ciao Corona*) will enroll a regionally representative,  
32 random sample of schools in the canton of Zurich, where 18% of the Swiss population live.  
33 Children aged 5 to 16 years, attending classes in primary and secondary schools are invited.  
34 Venous blood and saliva samples are collected for SARS-CoV-2 serological testing after the  
35 first wave of infections (June/July 2020), in fall (October/November 2020), and after winter  
36 (March/April 2021). Venous blood is also collected for serological testing of parents and  
37 school personnel. Bi-monthly questionnaires to children, parents and school personnel cover  
38 SARS-CoV-2 symptoms and tests, health, preventive behavior, lifestyle and quality of life  
39 information. Total seroprevalence and cumulative incidence will be calculated. Hierarchical  
40 Bayesian logistic regression models will account for sensitivity and specificity of the  
41 serological test in the analyses and for the complex sampling structure, i.e., clustering within  
42 classes and schools.

43 **Ethics and dissemination** The study was approved by the Ethics Committee of the Canton  
44 of Zurich, Switzerland (2020-01336). The results of this study will be published in peer-  
45 reviewed journals and will be made available to study participants and participating schools,  
46 the Federal Office of Public Health, and the Educational Department of the canton of Zurich.

47 **Trial registration number** NCT04448717.

48

49 **Keywords:** SARS-CoV-2, COVID-19, children, adolescents, school, protocol.

50 **Strengths and limitations of this study**

- 51 • *Ciao Corona* is a large, prospective school-based cohort study and will provide robust  
52 data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
53 seroprevalence, transmission routes and immunity over time in a representative  
54 sample of school children.
- 55 • The longitudinal design will allow describing temporal trends of immunity to SARS-  
56 CoV-2 infection and to evaluate effects of school structure and preventive measures.
- 57 • This study will inform goal-oriented policy decisions in school management during  
58 subsequent outbreaks.
- 59 • Participation bias, missing questionnaires, desirability bias, and loss of follow up may  
60 occur. The validity of serological tests may also hamper results.

61

## 62 Introduction

63

64 Decisions on school opening or closing during the severe acute respiratory syndrome

65 coronavirus 2 (SARS-CoV-2) pandemic vary greatly across and even within countries. While

66 some countries kept schools mostly open (e.g., Sweden, Australia) or reopened early (e.g.,

67 Denmark), others opted for prolonged closing with decision on reopening in late summer

68 2020 pending (e.g., the US, Italy, Ireland). Early school closure in response to pandemic was

69 partly guided by analogy of transmission of other viruses, such as influenza [1,2], but current

70 reports suggest that the susceptibility and transmissibility of children may be largely different

71 for SARS-CoV-2 compared [3]. Lower prevalence of SARS-CoV-2 infection is reported in

72 younger children – potentially as they are infected less frequently or as infections are more

73 frequently asymptomatic and thus underestimated [4–6]. Although children may infect others

74 less often than adults, their exact role in transmission pathways is still not clear [7].

75 A few studies have reported population-level seroprevalence of SARS-CoV-2,

76 including the population of children [4,5]. Such studies focused on households, leaving the

77 role of schools in SARS-CoV-2 transmission unclear, especially as they were often

78 conducted during school closure. As most of school-aged children and adolescents' social

79 interactions take place in family and school [8], schools could play a crucial role in spreading

80 the infection. Currently, mostly anecdotal evidence and case studies of SARS-CoV-2

81 infection spread in schools exist [9,10].

82 Many schools were or still are closed worldwide in response to the pandemic, without

83 solid arguments for or sufficient understanding of potential consequences of such a policy

84 [11]. 1.6 billion learners worldwide (90% of all) were affected by school closure [12]. In the

85 US, school closure was coordinated on state and district level, with all US public schools

86 eventually closing from March 25<sup>th</sup>, 2020 [13]. The opening of the schools might be delayed

87 in many districts, and the exact mode of teaching is still not clear [14]. In Switzerland,

88 schools were closed from March 16<sup>th</sup> to May 10<sup>th</sup>, 2020 (switching to home and online

89 schooling), then partly reopened until June 7<sup>th</sup> (e.g., teaching in half-classes, restricting larger  
90 group activities, reducing school care groups), when regular teaching resumed again [15].

91 There is an urgent need for representative, population-based studies on children and  
92 adolescents especially in the school setting, to answer questions about the prevalence,  
93 infection routes, asymptomatic cases, risk factors, and duration of immunity to SARS-CoV-2  
94 infection. This article reports the design and protocol of a longitudinal school-based  
95 seroprevalence study conducted in the largest canton of Switzerland. The study is part of a  
96 large nationally coordinated research network *Corona Immunitas*, and one of the first and  
97 largest representative studies of SARS-CoV-2 spread in children and adolescents in schools,  
98 globally.

99  
100

## 101 [Methods and analysis](#)

102

### 103 [Study overview, design and population](#)

104

#### 105 **Study objectives**

106 The study focuses on the seroprevalence and potential clustering of SARS-CoV-2 infection in  
107 children and adolescents attending school, as well as history, symptoms, and risk factors for  
108 SARS-CoV-2, health, lifestyle and quality of life outcomes. It aims to address the following  
109 objectives:

- 110 1. To repeatedly determine the seroprevalence of SARS-CoV-2 antibodies in school-aged  
111 children covering grades one to eight (approximately 6-16 years old) after the lockdown  
112 and the subsequent reopening of schools (June/July 2020), three months after the start  
113 of the next school year (October/November 2020), and after the winter (March/April  
114 2021);
- 115 2. To examine clustering of seropositive cases within classes, schools and districts, and  
116 temporal evolution of the clusters;

- 117 3. To determine the proportion of asymptomatic children and adolescents with SARS-  
118 CoV-2 antibodies;
- 119 4. To determine the duration of the acquired immunity by examining new infections in  
120 children with positive serology and temporal persistence of detectable SARS-CoV-2  
121 antibodies;
- 122 5. To identify sociodemographic, exposure, hygiene, school- and family-based behavioral  
123 and environmental risk factors for SARS-CoV-2 infection;
- 124 6. To assess how school-children and their families adjust their lives and adopt preventive  
125 measures for SARS-CoV-2 over extended periods of time, and how quality of life is  
126 affected by the epidemic and preventive measures imposed or recommended by health  
127 authorities;
- 128 7. To assess how schools adopt preventive measures for SARS-CoV-2 infection over  
129 extended periods of time, and how they influence the infection rate;
- 130 8. To assess seroprevalence, clustering, and possible routes of transmission to and from  
131 children, school personnel and parents.

132

### 133 **Study design**

134 This is a longitudinal, population-based observational study in a regionally-representative  
135 cohort of children and adolescents from randomly selected schools and classes in the canton  
136 of Zurich, Switzerland. The study is embedded in a Swiss-wide research program *Corona*  
137 *Immunitas* ([www.corona-immunitas.ch](http://www.corona-immunitas.ch)), where another 25'000 persons (mostly adults) will  
138 be enrolled in over 20 prospective studies with fully aligned study protocols.

139 Children participants were enrolled from June 16<sup>th</sup> to July 9<sup>th</sup>, 2020, whereas parents and  
140 school personnel are enrolled from August 20<sup>th</sup> to September 5<sup>th</sup>. The follow-up of enrolled  
141 children and school personnel is planned until April 2021.


142 The longitudinal design allows for monitoring the evolution of the epidemic, as well as  
143 the impact of school-based and other preventive measures. Three phases are pre-defined, with  
144 the possibility for adaptation (i.e., adding Phase IV) according to the dynamic of the  
145 pandemic:

- 146 ● Phase I (June to September 2020): Baseline estimate of seroprevalence of SARS-Cov-  
147 2 in school-children, parents and school personnel shortly after the lockdown and  
148 subsequent re-opening of schools.
- 149 ● Phase II (October/November 2020): Estimate of seroprevalence in the same cohort of  
150 children and school personnel after the summer holiday and three months of school.
- 151 ● Phase III (March/April 2021): Estimate of seroprevalence in children and school  
152 personnel after the winter season.

153

#### 154 **Study setting: primary and secondary schools in Switzerland**

155 One out of six (1.5 million) inhabitants of Switzerland live in the canton of Zurich.  
156 The canton is divided into 12 districts (Figure 1). Details on population characteristics and  
157 school system are provided in the online data supplement.



158

159 **Figure 1** Districts of canton of Zurich: population density, count, and targeted number of  
160 enrolled schools

161

## 162 **Ethical aspects**

163 The study was approved by the Cantonal Ethics Committee Zurich (2020-01336). Written  
164 informed consent is obtained from parents or legal guardians (referred to as parents further  
165 on) of participating children. Children aged 14 years and older can confirm the consent  
166 themselves. Additional informed consent is obtained for biobanking plasma samples for  
167 subsequent testing within the scope of the SARS-CoV-2 seroprevalence study.

168

## 169 **Schools: sampling and sample size**

170 Random selection of schools is stratified within districts of the canton, and random selection  
171 of classes is stratified within lower, middle and upper levels of schools. All children



172 attending the selected classes are invited, except in mixed-age classes (only students from the  
173 eligible grades invited).

174 Primary schools are selected randomly, and the closest secondary school  
175 geographically is matched. The targeted number of schools to enroll per district ranges from  
176 2 to 10 depending on the district size. After initial invitation round, school participation rate  
177 is assessed and additional schools are selected within required districts, until the aimed  
178 number is reached, or further recruitment would not be feasible. Population sizes and targeted  
179 number of enrolled schools within districts is depicted in Figure 1.

180 The overall targeted number of schools is 58 (29 primary and 29 secondary schools).  
181 We aim to invite at least 3 classes and at least 40 children per school level. The number of  
182 classes and children to invite will be reassessed after calculating the average children  
183 participation rate in the first week of enrollment. If needed, additional classes will be invited,  
184 aiming to enroll at least 40 children per school level. Assuming a participation rate of 60-  
185 80% per class, we would enroll 2100-2800 children in June/July 2020. We expect a  
186 seroprevalence rate of 1 to 5% based on the existing research [4]. Depending on the  
187 specificity and sensitivity parameters of the test, we expect precision of about  $\pm 2\%$ .

188

### 189 **Population: definition**

190 Children and adolescents residing in Switzerland and attending a selected public or  
191 private, primary or secondary school (approximate age 5 to 16 years) in the canton of Zurich  
192 are eligible for the study, as well as their parents living in the same household, and the entire  
193 personnel of participating schools. Main exclusion criteria are small school size (for schools)  
194 and suspected or confirmed infection with SARS-CoV-2 during testing (for participants). The  
195 1<sup>st</sup>-2<sup>nd</sup>, 4<sup>th</sup>-5<sup>th</sup> and 7<sup>th</sup>-8<sup>th</sup> school grades are included. Third, 6 and 9 grades are excluded as  
196 these students may move to another school after the summer break, and follow-up would be  
197 compromised. In age-mixed learning classes in primary schools, only 1 and 5 grades are

198 included as children in other grades potentially change the class after the summer break.  
 199 Detailed inclusion and exclusion criteria are provided in the online data supplement.


200

201 [Study procedures](#)

202

203 **Recruitment and study timeline**

204 The process of recruitment, communication with invited schools, children and their parents,  
 205 and testing, is depicted in Figure 2. Randomly selected schools receive an email from the  
 206 study group, including study information, link to study website ([www.ciao-corona.ch](http://www.ciao-corona.ch)),  
 207 informational videos in multiple languages for schools, parents, and children. Further details  
 208 on recruitment process are provided in the online data supplement.



209

210 **Figure 2** Timeline of study recruitment, serological testing, and follow up

211 Note that the children’s questionnaire includes questions for parents. Timing of testing and  
 212 questionnaires is approximate and will depend on the development of the pandemic.

213

214 **Collection of samples and testing at schools**

215 At each of the planned testing phases, the study team will come to the participating school for  
 216 half or full day, depending on school size. Testing will take place in a sufficiently large room,  
 217 in small groups of participating children, with all necessary hygiene and distancing

218 precautions. First, information is provided, child's identity and consent confirmed, and saliva  
219 collected. Venous blood samples will be collected at supine position with the help of  
220 anesthetic patches, applied 45-60 min prior to venipuncture. Participating children receive a  
221 small age-appropriate gift (worth 5-20\$) at the end of each testing.

222 Adults will be invited for testing in schools or at a testing center. Personal support to  
223 fill in the online questionnaire will be offered during testing. Venous blood will be collected.  
224 Collected samples are stored, cooled and transported to the laboratory daily after the testing is  
225 finished.

226

## 227 **Measurements**

228 Summary information of specimen and questionnaires collected is provided in Table 1.

229

230

231 **Table 1** Summary of testing and measurements in study populations

	<b>School principals</b>	<b>Children</b>			<b>Parents</b>		<b>School personnel</b>	
<b>Measurement</b>	<b>Questionnaire</b>	<b>Serological testing</b>	<b>Baseline questionnaire</b>	<b>Follow-up questionnaire</b>	<b>Serological testing</b>	<b>Questionnaire</b>	<b>Serological testing</b>	<b>Questionnaire</b>
Frequency	5 times	3 times	3 times <sup>a</sup>	Bi-monthly	2 times	Once	2 times	Bi-monthly
<b>Specimen</b>								
Venous blood		X			X		X	
Saliva		X <sup>b</sup>						
<b>Collected information</b>								
School structure	X							
Preventive measures	X		X	X		X		X
Sociodemographic			X			X		X
SARS-CoV-2 symptoms and	X		X	X		X		X

diagnosis in		
households		
Household	X	X
composition		
Quality of life	X	X
Lifestyle	X	

232 <sup>a</sup> – full questionnaire at baseline, shortened version at follow-up; <sup>b</sup> – depending on the results of the validation study; SARS-CoV-2, severe acute respiratory syndrome

233 coronavirus 2.

234

235

236

## 237 **Blood and saliva samples for serological testing**

238 For each child and adult participant, one sample (9 mL for children and 4.9 mL for  
239 adults) of venous blood will be collected for the assessment of SARS-CoV-2 antibodies.

240 Plasma will be separated, aliquoted into 1mL tubes and biobanked at -20°C until testing.

241 Saliva samples are collected in clean tubes and enriched with virus transport medium.

242 Saliva will first be validated for serological testing. If serological testing in saliva is deemed  
243 sufficiently accurate, venous blood sampling might not be necessary in further testing phases.

244 Conversely, if serological testing in saliva is deemed not accurate enough, saliva sample  
245 collection will not be continued.

246 For serological analysis, an in-house developed bead-based binding assay based on  
247 the Luminex technology will be used for children. The ABCORA test (version 2.0) provides  
248 a highly differentiated picture of the immune response: immunoglobulins G (IgG), M (IgM)  
249 and A (IgA) antibodies against four SARS-CoV-2 targets (receptor binding domain (RBD),  
250 spike proteins S1 and S2), and the nucleocapsid protein (N) of SARS-CoV-2) are analyzed,  
251 resulting in twelve analyzed parameters. Owing to the broad assessment of serological  
252 parameters, the ABCORA 2.0 test provides an estimate of infection recency. Based on the  
253 ABCORA 2.0 results the seroconversion status of a sample will be classified as positive,  
254 weakly reactive, indeterminate, or negative, based on pre-specified threshold values of  
255 detected antibody reactivities. In a validation study (unpublished) of 104 samples of SARS-  
256 CoV-2 reverse transcription polymerase chain reaction (RT-PCR) positive persons and 251  
257 samples of pre-pandemic, healthy blood donors, test had sensitivity of 93.3-95.2% (compared  
258 to sensitivity of 88.5%-93.3% in commercially available tests) and specificity of 98.4-99.6%  
259 (depending on the threshold definition of positive and negative cases).

260 For school personnel and parents, the SenASTrIS (Sensitive Anti-SARS-CoV-2 Spike  
261 Trimer Immunoglobulin Serological) assay developed by the Centre Hospitalier Universitaire  
262 Vaudois (CHUV), the Swiss Federal Institute of Technology in Lausanne (EPFL) and the

263 Swiss Vaccine Center will be used [16]. The test is used by all study sites of the nationally  
264 coordinated research program *Corona Immunitas*.

265

### 266 **Collection of questionnaire data**

267 Detailed information of data collected with each questionnaire is provided in the online data  
268 supplement. Briefly, baseline and follow up questionnaires are filled online (when necessary,  
269 on paper or over phone) for participating children by parents together with the child, and  
270 school personnel (see Figure 2). Follow up questionnaires are sent approximately bi-monthly,  
271 adapting to the school year timing, at least until April 2021. School principals will fill in  
272 questionnaires at and between each testing phase.

273

### 274 [Study data](#)

275

### 276 **Data management**

277 Study data will be collected in REDCap (Research Electronic Data Capture), a secure, web-  
278 based application with access restricted to selected study personnel. The database will also be  
279 used to send out online surveys to school personnel and parents, and deliver study results per  
280 email. Further details are provided in the online data supplement.

281

### 282 **Data analysis**

283 Descriptive analysis of participant sociodemographic, lifestyle, and behavior information will  
284 be performed. Total seroprevalence and cumulative incidence will be calculated, as well as  
285 age-, time- and region-specific estimates. In order to also include the sensitivity and  
286 specificity of the serological test in the analyses and account for the complex sampling  
287 structure (clustering within classes and schools), hierarchical Bayesian logistic regression  
288 models will be used.[4] The total numbers of school children in the respective grades per  
289 district will be used for post-stratification, so that the estimates are representative for the  
290 demographics of the canton of Zurich.

291 Associations with health and quality of life outcomes will be assessed with multiple  
292 regression models. Other planned estimates include proportion of seropositive individuals  
293 who have been asymptomatic, risk factors for infection at individual and school level.  
294 Associations of levels of IgG, IgM and IgA antibodies with symptoms and risk factors will be  
295 assessed.

296

### 297 **Patient and public involvement**

298 The study was initiated together with the Educational Department of the canton of Zurich.  
299 Several school principals were consulted during the development of the protocol to ensure  
300 feasibility of the planned study procedures. Early feedback was collected from children and  
301 parents invited to participate, in order to adapt the communication strategies and channels.  
302 Further feedback was collected from enrolled children and school principals during the first  
303 testing phase, in order to adapt subsequent testing phases and adult testing. Numerous online  
304 informational sessions, encouraging open exchange and feedback, were organized for school  
305 principals, personnel and parents of the children. Results of individual tests will be  
306 communicated to the participants, and overall study results disseminated to participating  
307 schools. Findings will be disseminated in lay language in the national and local press, to the  
308 national and regional educational and public health departments and to the website of the  
309 study.

310

### 311 Discussion

312

313 This longitudinal population-based cohort study is unique for its focus on children and  
314 adolescents in schools. Despite the lacking knowledge how schools contribute to the spread  
315 of SARS-CoV-2 infection, major policy decisions on temporary school closure or schedules  
316 have been implemented globally in response to the pandemic. This study will contribute to



317 explain the role of schools in order to define the necessary and sufficient preventive measures  
318 to balance infection control and impact of school closure.

319         Currently available population-based seroprevalence studies, which have included  
320 children, were mostly conducted in household setting. In May 2020, only 0.8% of children  
321 aged 5-9 years were seropositive for SARS-Cov-2 in Geneva, Switzerland, in contrast to  
322 9.6% of children and adolescents aged 10-19 years and 9.9% of adults aged 20-49 years [4].  
323 In April and May 2020, 3.8% of children and adolescents aged 0-19 years were seropositive  
324 in Spain, compared to 4.5% to 5.0% in older age groups [5]. In contrast, the current study  
325 will primarily consider schools. By analyzing seroprevalence on individual, class and school  
326 level, as well as in parents and school personnel, we will be able to identify clusters within  
327 these structures. Such knowledge could help to decide if individual classes or whole schools  
328 need to be closed to prevent SARS-CoV-2 infection spread. In addition, by testing the entire  
329 school personnel, it will inform which employees at schools are the most susceptible to  
330 infection.

331         Only few related planned or ongoing studies have been reported worldwide. In the  
332 UK, a study run by Public Health England aims to test seroprevalence in child care facilities  
333 and schools in England in May/June, July, and end of autumn 2020 [17]. However, it is not  
334 clear if the sampling of schools will be random or stratified by regions or if the structure  
335 within schools (classes) will be considered. A smaller study in Berlin, Germany, aims to test  
336 24 randomly selected schools, including 20-40 children and adolescents (500-1000 in total)  
337 and 5-10 staff members at each school [18].

338         The results of this study will likely be generalizable to other cantons in Switzerland  
339 and also worldwide, particularly to high- and middle-income countries. The canton of Zurich  
340 includes both urban and rural settings, as well as an ethnically and linguistically diverse  
341 population. Although the rates of seroprevalence are always location- and time- specific, we  
342 believe that the longitudinal design will allow us to investigate many stages of the pandemic.

343           Due to urgency to launch the study, it faces a few challenges. First, high participation  
344 rate of schools and children is required for sufficient power to analyze different regions and  
345 clusters within classes and schools. We believe that the high public interest will lead to  
346 increased participation, which could otherwise be rather limited in a study collecting venous  
347 blood samples in children. In fact, in the initial testing phase in June/July 2020, 55 schools  
348 and more than 2500 children were successfully enrolled. Second, the protocol of the  
349 longitudinal study will have to be flexible as the pandemic and serological testing methods  
350 develop. For this reason, the specific time points of serological testing cannot be fixed in  
351 advance (e.g., in case of school closure during the course of the study). Similarly, in further  
352 testing phases, it might be sufficient to do the serological testing in saliva or blood,  
353 depending on the outcome of the validation of serological testing in saliva. Finally, in order  
354 to recruit a sufficient number of schools still before school summer holidays, three rounds of  
355 invitations were needed, leading to potential over- or under-sampling of schools in certain  
356 districts. However, the sampling discrepancies can be adjusted with weighing of results.

357

## 358 **Conclusions**

359 This population-based cohort study with randomly selected schools and classes across the age  
360 range for mandatory school time offers a unique opportunity to observe the longitudinal  
361 spread of SARS-CoV-2 infection in children in schools, as well as in their parents and school  
362 personnel, thus studying the whole school community. It will report SARS-CoV-2  
363 seroprevalence in children by age groups and regions, provide essential information on  
364 possible transmission routes and immunity over time, and assess individual and school-level  
365 risk factors for infection. The longitudinal design will allow describing temporal trends of  
366 immunity to SARS-CoV-2 and evaluating effects of school structure and preventive  
367 measures. It will inform goal-oriented policy decisions in school management during  
368 subsequent outbreaks.

369

370 **Ethics and dissemination**

371 The study was approved by the Ethics Committee of the Canton of Zurich, Switzerland  
372 (2020-01336). The results of this study will be published in peer-reviewed journals and will  
373 be made available to study participants and participating schools, the Federal Office of Public  
374 Health of Switzerland, and the Educational Department of the canton of Zurich.

375

## References

- 376 1 Litvinova M, Liu QH, Kulikov ES, *et al.* Reactive school closure weakens the network  
377 of social interactions and reduces the spread of influenza. *Proc Natl Acad Sci U S A*  
378 2019;**116**:13174–81. doi:10.1073/pnas.1821298116
- 379 2 Cauchemez S, Ferguson NM, Wachtel C, *et al.* Closure of schools during an influenza  
380 pandemic. *Lancet Infect. Dis.* 2009;**9**:473–81. doi:10.1016/S1473-3099(09)70176-8
- 381 3 Viner RM, Russell SJ, Croker H, *et al.* School closure and management practices  
382 during coronavirus outbreaks including COVID-19: a rapid systematic review. *Lancet*  
383 *Child Adolesc. Heal.* 2020;**4**:397–404. doi:10.1016/S2352-4642(20)30095-X
- 384 4 Stringhini S, Wisniak A, Piumatti G, *et al.* Seroprevalence of anti-SARS-CoV-2 IgG  
385 antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.  
386 *Lancet* 2020;**0**. doi:10.1016/S0140-6736(20)31304-0
- 387 5 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, *et al.* Prevalence of SARS-CoV-2 in  
388 Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.  
389 *Lancet (London, England)* 2020;**0**. doi:10.1016/S0140-6736(20)31483-5
- 390 6 Gudbjartsson DF, Helgason A, Jonsson H, *et al.* Spread of SARS-CoV-2 in the  
391 Icelandic Population. *N Engl J Med* 2020;**382**:2302–15. doi:10.1056/NEJMoa2006100
- 392 7 Lee B, Raszka W V. COVID-19 Transmission and Children: The Child is Not to  
393 Blame. *Pediatrics* 2020;:e2020004879. doi:10.1542/peds.2020-004879
- 394 8 Mossong J, Hens N, Jit M, *et al.* Social Contacts and Mixing Patterns Relevant to the  
395 Spread of Infectious Diseases. *PLoS Med* 2008;**5**:e74.  
396 doi:10.1371/journal.pmed.0050074
- 397 9 National Centre for Immunisation Research and Surveillance (NCIRS). COVID-19 in  
398 schools-the experience in NSW. 2020.
- 399 10 Fontanet A, Grant R, Tondeur L, *et al.* SARS-CoV-2 infection in primary schools in  
400 northern France: A retrospective cohort study in an area of high transmission. *medRxiv*  
401 2020;:2020.06.25.20140178. doi:10.1101/2020.06.25.20140178
- 402 11 Masonbrink AR, Hurley E. Advocating for Children During the COVID-19 School  
403 Closures. *Pediatrics*. 2020. doi:10.1542/peds.2020-1440
- 404 12 School closures caused by Coronavirus (Covid-19).  
405 <https://en.unesco.org/covid19/educationresponse> (accessed 17 Jul 2020).
- 406 13 The Coronavirus Spring: The Historic Closing of U.S. Schools (A Timeline) -  
407 Education Week. <https://www.edweek.org/ew/section/multimedia/the-coronavirus-spring-the-historic-closing-of.html> (accessed 13 Jul 2020).
- 408  
409 14 Data: When Will School Start This Fall? - Education Week.  
410 <https://www.edweek.org/ew/section/multimedia/data-when-will-school-start-this-fall.html> (accessed 13 Jul 2020).
- 411  
412 15 Swiss National COVID-19 Science Task Force. Situation report. <https://ncs-tf.ch/en/situation-report> (accessed 13 Jul 2020).
- 413  
414 16 Fenwick C, Croxatto A, Coste AT, *et al.* Changes in SARS-CoV-2 Antibody  
415 Responses Impact the Estimates of Infections in Population-Based 1 Seroprevalence  
416 Studies 2. *medRxiv* 2020;:2020.07.14.20153536. doi:10.1101/2020.07.14.20153536
- 417 17 Ladhani S, Ramsay M, Amirthalingam G, *et al.* COVID-19 Surveillance in Children  
418 attending preschool, primary and secondary schools. 2020.  
419 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891762/sKID_protocol_v1.3.pdf)  
420 [nt\\_data/file/891762/sKID\\_protocol\\_v1.3.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891762/sKID_protocol_v1.3.pdf)
- 421 18 Berlin’s testing strategy – Charité starts screening program for staff from childcare  
422 centers and school-based study: Charité – Universitätsmedizin Berlin.  
423 [https://www.charite.de/en/service/press\\_reports/artikel/detail/berlins\\_testing\\_strategy\\_](https://www.charite.de/en/service/press_reports/artikel/detail/berlins_testing_strategy_charite_starts_screening_program_for_staff_from_childcare_centers_and_sc/)  
424 [charite\\_starts\\_screening\\_program\\_for\\_staff\\_from\\_childcare\\_centers\\_and\\_sc/](https://www.charite.de/en/service/press_reports/artikel/detail/berlins_testing_strategy_charite_starts_screening_program_for_staff_from_childcare_centers_and_sc/)  
425 (accessed 13 Jul 2020).

426

427 **Acknowledgements** We greatly appreciate the uncomplicated and supportive collaboration  
428 of school principals and teachers, and truly thank all children and their parents for their  
429 willingness to participate in this study. We also thank the “Volksschulamt” of the canton of  
430 Zurich for providing us with the comprehensive list of all schools and classes of the canton.  
431 We would like to thank Jacob Blankenberger (Epidemiology, Biostatistics and Prevention  
432 Institute, University of Zurich) for his support in planning the testing of parents and school  
433 personnel and Jörg Böni (Institute of Medical Virology, University of Zurich) for his  
434 administrative support and expertise in regard to sampling, storage and transport of bio  
435 samples.

436

437 **Author’s contributions** SK and MP initiated the project and preliminary design, with  
438 support of JF. SK, MP, CB, TR, RJ and AU developed the design and methodology. SK, RJ,  
439 AU and TR are responsible for the recruitment process and testing at schools. SRH and JB  
440 contributed to the design of the statistical methods and statistical analysis plan. Analysis will  
441 be performed by SRH and JB. AT and IA contributed to the design of the study methodology  
442 and take responsibility for the storage and analysis of samples. AU wrote the first draft of the  
443 manuscript. All authors provided edits and critiqued the manuscript for intellectual content.

444

445 **Funding** This study is part of *Corona Immunitas* research network, coordinated by the Swiss  
446 School of Public Health (SSPH+), and funded by fundraising of SSPH+ that includes funds  
447 of the Swiss Federal Office of Public Health and private funders (ethical guidelines for  
448 funding stated by SSPH+ will be respected), by funds of the Cantons (Vaud, Zurich and  
449 Basel) and by institutional funds of the Universities. Additional funding, specific to this study  
450 (Ciao Corona) is available from the Fondation les Murons and from the Pandemic Fund of  
451 the University of Zurich Foundation. The funder/sponsor did not participate in the work.

452

453 **Competing interests** None declared.